Breaking news! After implementation of newborn screening for SCID on the 1st of January 2021, the Netherlands are now delving into newborn screening for XLA. The research project ‘Stop XLA’ is nominated for the Medical Inspiration Award 2020 (ZonMw). This award is presented to research projects with an inspirational collaboration between researchers, patients and patient organizations. Please support this important research project on newborn screening for XLA and vote via www.zonmw.nl/stemnu. Tip: use Google Chrome as a web browser to easily translate the page to English.
‘Stop XLA’ Medical Inspiration Award 2020 Campaign Video
X-linked agammaglobulinemia (XLA) is a severe antibody deficiency. XLA patients develop severe and recurrent infections. Without treatment, XLA can result in chronic lung disease and mortality at a young age. Early diagnosis and early treatment will prevent infections and reduce secondary complications. Newborn screening for XLA will therefore lead to better outcomes for all future XLA patients worldwide.